

BIOCRYST PHARMACEUTICALS INC

Form 8-K

October 20, 2003

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) October 20, 2003

**BIOCRYST PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

DELAWARE

(State or Other Jurisdiction of Incorporation or Organization)

000-23186  
(Commission File Number)

62-1413174  
(I.R.S. Employer Identification No.)

2190 Parkway Lake Drive; Birmingham, Alabama 35244  
(Address and Zip Code of Principal Executive Offices)

(205) 444-4600  
(Registrant's Telephone Number, Including Area Code)

NONE

(Former Name or Former Address, if Changed Since Last Report)

1

---

**Item 7. Financial Statements and Exhibits**

(c) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated October 20, 2003 entitled BIOCRYST REPORTS THIRD QUARTER 2003 FINANCIAL RESULTS.

# Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

## Item 12. Results of Operations and Financial Condition:

On October 20, 2003, BioCryst Pharmaceuticals, Inc. issued a news release announcing its financial results for the quarter ended September 30, 2003. A copy of the news release is attached hereto as exhibit 99.1 and is incorporated by reference into Item 12 of Form 8-K.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIOCRYST PHARMACEUTICALS, INC.

Date: October 20, 2003

/s/ Michael A. Darwin

Michael A. Darwin  
Chief Financial Officer and  
Chief Accounting Officer

### INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Description</b>	<b>Sequentially Numbered Page</b>
99.1	Press release dated October 20, 2003 entitled BIOCRYST REPORTS THIRD QUARTER 2003 FINANCIAL RESULTS .	3